Table 3

Allelic HR of all-cause and CVD mortality for rs10911021 in the two study cohorts and in the combined analysis

JKSGMSJKS + GMS
HR (95% CI)PHR (95% CI)PHR (95% CI)P
All-cause mortality
 Model 11.32 (1.07–1.64)0.0101.30 (1.01–1.69)0.0441.32 (1.12–1.55)0.0011
 Model 21.33 (1.07–1.65)0.00931.32 (1.02–1.71)0.0381.32 (1.12–1.56)0.0009
 Model 31.50 (1.19–1.88)0.00061.23 (0.95–1.60)0.121.35 (1.14–1.60)0.0005
CVD mortality
 Model 11.51 (1.12–2.04)0.0077
 Model 21.50 (1.11–2.03)0.0085
 Model 31.72 (1.24–2.38)0.0011
  • Model 1, rs10911021; Model 2, rs10911021, sex, age, and race; Model 3, rs10911021, sex, age at study entry, race, BMI, HbA1c, CKD, microalbuminuria/macroalbuminuria, and glucose-lowering therapy.